Tumor lysis syndrome induced by tebentafusp.
Immunotherapy
; 15(16): 1363-1368, 2023 11.
Article
em En
| MEDLINE
| ID: mdl-37661909
Tebentafusp is a new treatment for a type of eye cancer called uveal melanoma. It helps the body's defense system fight against cancer cells and has shown promise in helping patients live longer. However, not all patients with uveal melanoma can use this treatment. Only those who have a specific gene marker called HLA-A*02:01-positive can benefit from it. Like any new treatment, tebentafusp may have some side effects. One of them is called cytokine-release syndrome, which can cause symptoms like rash, fever and flu-like feelings. Usually, this side effect is not serious and can be treated well. There was a rare but serious case where one patient had a bad reaction after getting only one dose of tebentafusp. This reaction is called tumor lysis syndrome, which happens when cancer cells break down quickly and release harmful substances into the blood. This can be life-threatening. Thankfully, the patient received the right treatment and got better. This information is shared here with doctors and patients, so they know about possible side effects and can use tebentafusp safely.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Uveais
/
Síndrome de Lise Tumoral
/
Melanoma
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article